Benefits are recognized when Baricitinib is co-administered with Remdesivir for the treatment of COVID-19. Low-molecular-weight heparin and new anticoagulant (NOAC) are also newly added as COVID-19 benefits. Lopinavir / Ritonavir (combination therapy), Hydroxychloroquine, and Ribavirin are eliminated from drugs covered by COVID-19.

On the 31st, the MOHW revised and issued some 'details on the standards and methods for applying medical care benefits' with the above contents.

The amendment applies to treatments for MERS-CoV and COVID-19.

With regard to the target of administration, the standard for COVID-19 treatment will be clarified from the person who is conducting the co